IASLC WCLC 2021: Lurbinectedin-Doxorubicin a Safer Option for Relapsed Small Cell Lung Cancer Than Standard-of-Care Chemotherapy
Efficacy between the two treatment regimens appears to be comparable
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.